Benzinga | Aug 14, 2020 07:11AM EDT

BioXcel Therapeutics Q2 EPS $(1.06) Misses $(0.75) Estimate

BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.75) by 41.33 percent. This is a 96.3 percent decrease over losses of $(0.54) per share from the same period last year.